Synuclein quantitation in plasma using LC-MRM

Absolute quantification of synuclein proteoforms in plasma in patients with Synucleinopathies by LC-MRM mass spectrometry

Pons Marie-Laure¹,², Vignon Margaux¹, Vialaret Jérôme¹, Mondesert Etienne¹, Moreau Stéphane², Lehmann Sylvain¹ and Hirtz Christophe¹

¹ IRMB, Univ Montpellier, INM, INSERM, CHU Montpellier, (LBPC-PPC), Montpellier, France
² Shimadzu Corporation, Albert-Hahn-Straße, Duisburg – Germany

marielaurepons43@gmail.com (+33 4 67 33 71 73), margaux.vignon@umontpellier.fr (+33 4 67 33 04 20), j-vialaret@chu-montpellier.fr (+33 4 67 33 71 73), e-mondesert@chu-montpellier.fr (+33 4 67 33 83 46), sm@shimadzu.eu (+49-203-76870), sylvain.lehmann@umontpellier.fr (+33 4 67 33 71 23) and christophe.hirtz@umontpellier.fr (+33 4 67 33 04 20).

Corresponding author : Pons Marie-Laure, marielaurepons43@gmail.com (+33 4 67 33 71 73).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Synuclein quantitation in plasma using LC-MRM

Abstract

Background: Synucleinopathies include Parkinson’s disease (PD), Lewy body dementia (LBD) and Multiple system atrophy (MSA). Most studies of synucleinopathies rely on immunoassays to quantify total or oligomeric alpha synuclein. Immunoassay results are variable due to the inconstant nature of antibodies and different studies found higher, lower or equal levels of alpha synuclein between PD and control patients in biological matrixes. Mass spectrometry, has less inherent variability.

Methods: Therefore, we developed the first reliable and validated mass spectrometry method to quantify synuclein proteoforms in human plasma using liquid chromatography coupled to mass spectrometry with multiple reaction monitoring mode (LC-MRM) mass spectrometry,

Results: The study followed European and International guidelines (Food and Drug administration and European Medicines Agency) and paves the way for precise multiplex quantitation of synucleinopathies. Using a cohort of 143 patients with synucleinopathies and controls we found a peptide ratio and combination between \( \alpha \)-syn EQVTNVGGAVVTGVTAVAQK and \( \alpha/\beta \)-syn EGVLYVGSK peptides that discriminated PD patients from the other diseases (LBD, MSA and controls). The sensitivity and specificity (Area Under ROC Curve) of the method to distinguish between patients with PD and control patients was 0.84 and 0.76 (0.787), for PD vs LBD the values were 0.7 and 0.68 (0.743), and 0.85 and 0.85 (0.831) for PD vs MSA.

Conclusions: The developed and validated LC-MRM method presented here could be used in clinical to discriminate PD from other synucleinopathies and control patient.
Keywords: Parkinson’s disease, alpha synuclein, immunoassay, mass spectrometry, proteoforms, ratio and combination of peptides.
Synuclein quantitation in plasma using LC-MRM

Introduction

Synucleinopathies are a group of pathologies that share cognitive, motor, non-motor symptoms and molecular inclusions composed of alpha synuclein. The three most well-known and common such pathologies are Lewy bodies Dementia (LBD), Parkinson’s disease (PD) and multi system atrophy (MSA)\(^1\). There are three kinds of synuclein: alpha, beta and gamma synuclein, that are all present in pre-synaptic terminals in dopaminergic neurons.

Alpha synuclein inclusions, called Lewy bodies and Lewy neurites, are made of aggregated, fibrillar, phosphorylated, ubiquitinated and truncated alpha synuclein species. These inclusions are retrieved in the cytoplasm of the dopaminergic neurons for PD and LBD pathologies and found in oligodendrocytes for MSA patients\(^1\). Lewy bodies are responsible for the neurodegeneration observed in synucleinopathies\(^2\). Therefore, this protein and its proteoforms have been proposed as biomarkers for these pathologies\(^3\). Synuclein proteoforms include serine 129 phosphorylated, some C-terminal truncations and ubiquitination sites or alternatively spliced alpha synuclein isoforms with 126, 112, 98 and 41 amino acids\(^4\). Indeed, the alpha synuclein spliced variants have been found in different mRNA level in synucleinopathies. \(\alpha\)-syn alternative proteins also arise from a reading frameshift (+2 instead of +1) resulting in different and shorter protein than the full length alpha synuclein (140 aa). This type of species could potentially play a role in the pathogenesis of neurodegenerative disease\(^5\).

Beta synuclein is not detected in aggregates or fibrils in brains with synucleinopathies and has a lower propensity to aggregate than alpha synuclein due to the absence of
Synuclein quantitation in plasma using LC-MRM

the 73-83 AA part of the non-amyloid component domain\(^6\). Gamma synuclein has
been detected in fibril form in PD brains\(^7\).

For several years, synucleins have been studied, and especially alpha synuclein, due
to their potential biomarker value in neurodegenerative disorders. So far, detection
and quantification of synucleins (total, oligomeric and phosphorylated at S129) in
human biological fluids has mainly been achieved via antibody-based assays such as
ELISA\(^3,8\). This approach may undergo some bias due to nonspecific detection and
antibody affinity variability. Indeed, immunoassay kits gave highly variable results in
absolute concentration and with alpha synuclein level retrieved in biological fluid
(cerebrospinal fluid\(^9\), plasma and saliva).

To counteract antibody-based method (ELISA) issues, clinical mass spectrometry
(MS) approaches have been successfully developed to improve protein and
proteoform quantification\(^10\). Indeed, MS is a powerful tool thanks to accurate, specific
and multiplex quantitation. These performances are due to the analysis of mass on
charge (m/z) of ions from proteotypic peptides after sample ionisation\(^11\). In multiple
reaction monitoring (MRM), at least three transitions, corresponding to the
fragmentation of the precursor ion into products ions, are monitored\(^12\).

In conclusion, the concentration differences of alpha synuclein observed in
synucleinopathies in CSF, the lack of study using MS quantification (3), the risk of
interference by blood contamination during lumbar puncture\(^13\) and the high
expression of alpha synuclein in erythrocyte\(^14\), supports the notion that total alpha
synuclein in CSF is not a useful diagnostic biomarker for synucleinopathies\(^7\).
Synuclein quantitation in plasma using LC-MRM

Here we present a validated and targeted mass spectrometry method to quantify synucleins proteoforms in plasma patient samples with synucleinopathies. This quantification method was compared with sensitive immunoassay measurement.

Materials and methods

Reagents and internal standards

Recombinant human full-length alpha synuclein (α-syn) and the recombinant full-length α-syn with uniform $^{15}$N-label came from LGC (Teddington, UK). The recombinant beta and gamma synuclein (β-syn and γ-syn) with uniform $^{15}$N-label were purchased from Promise Advanced Proteomics (Grenoble, France). The beta and gamma recombinant light form came from Anaspec (Fremont, California, USA) and Interchim (Montluçon, France) respectively. Light protein standard concentration was determined for α-syn by electrochemiluminescence with the U-PLEX Human α-Synuclein immunoassay kit purchased from MesoScale Discovery system (Rockville, Maryland, USA). MS grade Trypsin/LysC, rLysC, Glu-C and Lys-N were purchased from Promega GmbH (Walldorf, Germany). Ammonium bicarbonate, perchloric acid, trifluoroacetic acid and human serum albumin (HSA) were ordered from Sigma Aldrich (Saint Quentin Fallavier, France). RP-W Cartridge tips were purchased from Agilent technologies (Santa Clara, California, USA). MS-grade liquid chromatography solvents: acetonitrile, water and formic acid were purchased from Biosolve (Dieuze, France). AQUA (absolute quantitation) peptides for α-syn-126/98; α-syn-112/98 and α-syn-41 came from Thermofisher scientific (Lincoln, Massachusetts, USA) with a purity of 99%. Specific peptides of the alternative α-syn and its mutated form were also purchased from Thermofisher scientific (Lincoln, Massachusetts, USA) with a
Synuclein quantitation in plasma using LC-MRM

purity of 95%. Goat serum (capra hircus) was ordered from Clinisciences (Nanterre, France).

Stock Solutions, Calibration Standards, and Quality Control (QC) samples

Protein and peptide standards were dissolved in 50 mM ammonium bicarbonate to a final concentration of 1µg/µl. Aliquots of 10 µl were dispensed into low protein-binding Eppendorf tubes and stored at -20 °C or -80 °C, according to the suppliers' instructions.

Method development and validation were performed on plasma QC samples at three concentration levels: low (45 ± 6.2) ng/ml, medium (87 ± 16.9 ng/ml) and high (230 ± 30.4 ng/ml), quantified by electrochemiluminescence (MesoScale Discovery).

Patient samples from the laboratory biobank were thawed at 4°C for one hour. They were put in a 50 ml falcon and mixed for several minutes. They were then re-aliquoted (50µl per tube) and stored at -80°C until analysis.

MS Calibration

9 points of calibration were prepared by diluting recombinant light α-syn, β-syn and γ-syn standards into goat (capra hircus) serum. Calibration ranges (detailed in Table S2 in supplemental data) were as follows: [0-5571] ng/mL for α-syn, [0-410] ng/mL for β-syn and [0-1401] ng/mL for γ-syn. The calibration range for labelled peptides (AQUA) including N-terminal peptide, peptides from α-syn isoforms, and peptides from α-syn alternative protein, were performed separately on 8 points and the concentration of each peptide is described in Table S3 in supplemental data. Peptide concentrations were calculated based on the calibration curve (weighting 1/x2) using Skyline software.
Synuclein quantitation in plasma using LC-MRM

Sample Preparation

95 µl of plasma samples were thawed on ice for 1 hour. Then 855 µl of deionised water was added. Samples were then supplemented with 5.7 µl of 10 ng/µl internal standard of recombinant labelled U-^{15}N alpha, beta and gamma synuclein in 50 mM ammonium bicarbonate. Samples were mixed and the proteins were precipitated by incubation on ice for 15 minutes with 142.5 µl of 70% perchloric acid. After incubation, samples were spun at 16,000 g for 15 min at 4°C, and the supernatants were collected into new LoBind tubes with the addition of 95 µl of 1% trifluoroacetic acid. After a volume reduction by vacuum-drying at room temperature (Speedvac, Labconco), the supernatants were cleaned up on RP-W cartridges using the AssayMap Bravo (Agilent technologies) into a LoBind 96 deep well plate. The cartridges were washed out with water at an aspiration speed of 10 µl/min and then samples were loaded on the cartridges at 5 µl/min. Proteins were washed out on bravo tips with 10% acetonitrile and 0.1% formic acid at 10 µl/min and eluted with 45% acetonitrile and 0.1% formic acid at 5 µl/min. Samples were evaporated dry at room temperature under vacuum for 1h30 using a Speedvac. The samples were reconstituted with 20µl of 50mM ammonium bicarbonate. Finally, 7 µl of 1µg/µl trypsin/lysC were added. Plasma samples were incubated for 4 hours at 37°C with gentle agitation (450 rpm). After incubation, 0.5 µL of formic acid was added to the samples.

Liquid chromatography-mass spectrometry multiple reaction monitoring analysis

Samples were analysed using a Shimadzu liquid chromatography system (Mikros) and a triple quadrupole - Shimadzu 8060 mass spectrometer (Duisburg, Germany) in
Synuclein quantitation in plasma using LC-MRM

developer ionization mode. 15µl of sample were injected on a ZORBAX SB-Aq (1 x 150
mm, 3.5 µm) column from Agilent technologies, at 35°C. The mobile phase A was
composed of water with 0.1% of formic acid and the mobile phase B was composed
of acetonitrile with 0.1% of formic acid. The solvent gradient consisted of a slow
increase of the organic solvent (phase B) from 0% to 30% over 30 min. Total run time
for the analysis was 40 min at a flow rate of 50µl/min. The minimum dwell time used
was 20 ms per peptide. The ion source parameters were 3 L/min for the nebulizing
gas flow, 10 L/min for the heating gas flow, 300°C for the interface temperature,
250°C for the desolvation line temperature, 400°C for the heat block temperature and
10L/min for the drying gas flow. Between three and six transitions were acquired for
each peptide in biological samples. Peptide position, selection and transitions of the
synucleins are described in Table S1 in supplemental data. The concentration of the
α-syn and β-syn peptides was determined by comparing unlabelled and labelled
peptides with LC-MRM analysis.

Analytical method validation

The intra and inter-assay repeatability was determined by analysing three QC
plasma at three different levels of α-syn (high, medium and low) per day over 4 days.

Sample stability was determined by analysis three aliquots of goat serum thawed on
ice or at room temperature for 6h. In addition, three QC plasma were stored until 48h
into the liquid chromatography autosampler at 4°C. Dilution and parallelism stability
was determined by dilution of goat serum with ammonium bicarbonate up to fourfold.

Matrix effect was determined by comparing the MS signal between spiked normal
goat serum (n=3) with heavy recombinant standards after digestion and spiked
solvent (n=3) after digestion at the same concentration.
Synuclein quantitation in plasma using LC-MRM

The lower limit of quantification was defined as the lowest concentration with a CV superior to 20% and a signal to noise ratio > 5.

Immunoassay

Plasma samples were analysed by immunochemiluminescence assay with a MesoScale Discovery. Plasma samples were diluted 200-fold for the determination of the total alpha synuclein concentration. All measurements were performed according to the manufacturer’s instructions. Antibodies were directed against α-syn C-terminal part (110-125) for capture (rabbit monoclonal antibody) and the mouse monoclonal detection antibody was against amino acids 15-125.

Patients and Biofluid Collection

All the participants gave their written consent to be enrolled in the study which was approved by the Montpellier University Hospital’s regional Ethics Committee. General characteristics of the 143 patients are presented in Table 1. Mean age of the population was 71 (±8.2) years, and 65 % were men. The cohort was divided in three disease groups: PD (n=82), LBD (n=32) and MSA (n=8) and a group of control patients (n=21). Control patients suffered from non-neurodegenerative diseases such as neurologic disorders including neuropathic affections (23.8 %), vascular affections (28.6 %), immunologic affections (28.6%) and hydrocephalus (19.0 %). Exclusion criteria for the control group was an abnormal Alzheimer biomarker profile (i.e. low Aβ 42/40 ratio and increased tau/ptau protein concentration). Regarding patients with Parkinson’s diseases, diagnosis was determined on average 11 (± 7.4) years before analysis. At diagnosis 41.9% had cognitive impairment and 69.7% presented non motor signs. Mean Hoehn and Yahr score (corresponding to the Unified Parkinson’s Disease Rating Scale V) was 2.4 (± 0.7). Unified Parkinson’s Disease Rating Scale II
Synuclein quantitation in plasma using LC-MRM and III scores were respectively, 19.7 (± 11.2) and 36 (± 18.9), corresponding to a light or moderate motor impairment. Plasma collected by venous puncture were stored at the Montpellier Neurobank (#DC-2008-417 of the certified NFS 96-900 CHU resource center BB-0033-00031). Authorization to handle personal data was granted by the French Data Protection Authority (CNIL).

Data analysis

The extraction of LC-MS chromatograms of synucleins peptides for quantification was realized using Skyline Software (20.1.0 version) and LabSolutions Insight Browser. Liquid chromatography-mass spectrometry with multiple reaction monitoring mode analyses were launched with LabSolutions software (5.99 version).

Statistical analysis was performed with MedCalc (19.0.3. version) and the normality of the data set were checked by Shapiro-Wilk test. Comparisons between the two groups were performed by Mann Whitney Wilcoxon method and clinical performance were assessed by ROC curve. A statistical model: $(\alpha\text{-syn}[\text{EQVTNVGAVVTGVTAVAQK}]^-0.011268 + \alpha/\beta\text{-syn}[\text{EGVLYVGSK}] \times 0.0096545)$ that defines the results was investigated by logistic regression with ‘backward’ and ‘enter’ methods. To select the model within the two methods, we set the following parameters: p-value <0.05, a minimal number of variables (2) and if both logistic regression methods gave the same coefficient result.

Results

Method development and optimization

To quantify alpha synuclein, we selected all the proteotypic peptides, except the C-terminal part that covers about 70% of the protein sequence. The C-terminal peptide
Synuclein quantitation in plasma using LC-MRM

is a long peptide (38 aa), mainly composed of acidic residues and many post-
translational modifications (phosphorylation, nitration and truncations) that impact the
MS signal. In plasma, this C-terminal peptide was constantly under the limits of
quantification. All the peptides and transitions were selected based on the sensitivity
and specificity observed in the biological sample compared to the spiked internal
labelled standards. All the MS parameters (tension applied in all quadrupoles) were
optimized for synuclein and haemoglobin peptides and are described in Table S1 in
supplemental data. We applied the same methodology for β-syn and γ-syn.

The entire workflow for the liquid chromatography-mass spectrometry with multiple
reaction monitoring mode analysis of the alpha synuclein peptides in plasma is
illustrated in Figure 1.

Analytical method validation

Both β-syn and γ-syn were constantly below the limit of quantification in the patient
samples and plasma QC samples at all three levels of α-syn concentration (high,
medium and low). The alternative splicing isoforms and alternative α-syn peptides
were also under the limit of quantification. α-syn and α/β-syn common peptides were
detected and quantified in all QC and patient samples.

Intra and Inter-assay repeatability was less than 20 % for alpha synuclein peptides in
low concentration QCs, except for TVEGAGSIAATGFVK peptides that were at 22%
in low QCs. In medium level QCs the coefficient of variation (CV) was ≤16% and
≤14% in high QCs for α-syn peptides, except for EGVVHGVAEKM and
(ac)MDVF MK peptides (CV >30%). Therefore, these peptides were excluded from
further clinical validation.
Synuclein quantitation in plasma using LC-MRM

The limit of quantification range was between 6.45 and 19.35 ng/ml for α-syn peptides and α/β-syn common peptides. The linearity ranged from 0 to 5571 ng/ml for α-syn peptides. The linearity range was from 0 to 5981 ng/ml for α/β-syn common peptides.

The synuclein peptides was stable when stored at 4°C until 48h, stable when thaw on ice until 6h and 4h at room temperature

The analytical validation parameters of the synuclein peptides are detailed in supplemental data in Table S4 and S5.

Clinical validation

In total 143 plasma samples were quantified, divided in 4 groups: the PD group (n=82), the MSA group (n=8), the LBD group (n=32) and the control group (n=21). All samples were acquired by MS and immunoassay. Details of the studied population are summarized in the Table 1.

To determine the clinical performance, we evaluated the area under ROC curve (AUC), the sensitivity and specificity, and the p-value to distinguish between pathological groups. The clinical performance results for alpha synuclein peptides in plasma patient samples are presented in details in Table 2.

All peptides were able to distinguish PD patients from control patients, except for the α-syn TVEGAGSIAAATGFVK peptide. The best performance peptide was α/β-syn EGVLYVGSK followed by α-syn QGVAEAAGK. Indeed, these peptides also separated the LBD group from PD and controls groups. The α/β-syn EGVLYVGSK peptide discriminated MSA patients from controls and gave the best clinical performance to distinguish PD and control patients. Respectively, the sensitivity and
Synuclein quantitation in plasma using LC-MRM

specificity were 0.84 and 0.76 for PD vs control. The clinical performance of the α/β-
syn EGVLYVGSK peptide (PD vs control) are illustrated via ROC curve in
supplemental data in Figure 1.

No peptides discriminated the PD group from the MSA group. To counteract this
issue, we applied a model combination of peptides. Thanks to logistic regression, a
peptide combination was found comprising these two following peptides: α-syn
EQVTNVGGAVVTGVTAVAQK and α/β-syn EGVLYVGSK, with the following
coefficient -0.011268 and 0.0096545, respectively. The data comparison graph
between groups for the peptide combination are described in Figure 2.

The obtained combination of these two peptides gave good discrimination of the PD
group from the MSA patients (P=0.0021). Due to their opposite coefficient signs, we
also investigated a ratio of the two alpha syn peptides to distinguish the four groups.

The best clinical performance for distinguishing PD from DLB or MSA was obtained
with the peptide combination. Indeed, a sensitivity and specificity of 0.7 ,0.68 and
0.84, 0.85 respectively were obtained. The ROC curve describing the clinical
performance of the peptide combination in PD vs LBD is demonstrated in Figure 3A,
and similarly, Figure 3B describes the clinical performance of the peptide
combination in PD vs MSA

Immunoassay quantification

The same plasma cohort has also been quantified by sensitive immuno-
chemiluminescence assay. The data comparison graph between disease is
presented in supplemental data Figure 2. No significant differences in α-syn level
quantified by immunochemiluminescence assay were observed between diseases. A
slightly lower level in the control group compared to the PD group was observed.
Correlation

All the alpha and beta synuclein peptides were correlated together (r>0.7). No correlation was found between patient characteristics (age, sex, sampling date) and synuclein peptides (including combinations and ratios) with -0.5<r<0.5. Also, no correlation between MS quantitation and immunochemiluminescence quantitation was found (-0.3<r<0.3). No correlation between motor (UPDRS II, III or V) or non-motor symptoms and cognitive symptoms were observed (-0.3<r<0.3).

Discussion

In this study MS clinical validation allowed us to observe a significant increase of five α-syn peptides, in PD plasma patients compared to control. The same patients were quantified by sensitive immunoassay for total alpha synuclein and no significant difference was observed between disease groups. The most important difference between these two methods is the variability introduced by the use of antibodies in immunoassays. In this case, the antibodies used targeted the C-terminal part of the proteins, which is problematic as this undergoes numerous post-translational modifications and truncations. These variations impact the total concentration of this protein as perceived by immunoassay\textsuperscript{15}. Indeed, the immunoassay readout did not correlate with any of the alpha synuclein peptides we observed in our MS pipeline. However, all the synuclein peptides correlated amongst themselves indicating that they are a robust measure of alpha synuclein levels.

One of our main aims of our study was to discriminate different synucleinopathies and controls. Regarding this particular point, we investigated a peptide combination and a ratio of alpha syn peptides and succeeded in differentiating PD from other groups with good sensitivity and specificity (more than 80% for sensitivity and
Synuclein quantitation in plasma using LC-MRM

between 70% and more than 80% for specificity depending on pathologies). This strategy was reminiscent of studies of AD that found that the ratio between amyloid peptides (Aβ40/42) can detect the disease. The ratio of Aβ40/42 in AD allows a better discrimination and enhanced clinical performance of AD patients even at prodromal stage compared to the quantification of the two separated peptides\(^1\). There may be some biological parallels here as alpha synuclein has already shown some similarity in aggregation mechanism with the amyloid beta peptides. Indeed, the peptides comprised in our peptide combination for alpha synuclein come from differentially affected parts of the protein. In the first place the α/β-syn EGVLYVGSK peptide (position 35-43 on sequence), is part of the N-terminal region. McGlinchey et al, 2021\(^7\) have described those residues 36-40 as being important for full-length structure and for the formation fibrils. These results mean that the N-terminal part can modulate the mechanism of amyloid formation and the molecular interactions of fibril assembly\(^7\). On the other hand the α-syn EQVTNVGGAVVTGVTAVAQK peptide (position 61-80 on sequence), is part of the non-amyloid component domain that constitutes the fibril core of the protein and is responsible of the aggregation process\(^7,8\).

While tantalizing, the utility of peptide combination/ratio will now need to be confirmed in a larger study. For example the specificity with which we can distinguish PD from MSA patients will need confirmation in a larger cohort, as MSA is rare with a prevalence estimated between 0.6 and 1.6 case per 100 000 habitants per year\(^9\). For PD, misdiagnosis is estimated at approximately 25 % and with well-established biomarkers, the disease could be detected 10 years earlier than it currently is\(^20,21\). We also note that none of our lead peptides correlated to PD severity (Unified Parkinson’s Disease Rating Scale UPDRS II, III and V). This could be due to the fact
Synuclein quantitation in plasma using LC-MRM

that most of the PD patients in our cohort were similarly affected with only light or moderate evolution.

Conclusion

Here we developed for the first time a validated method for the quantitation of synuclein peptides in plasma patients with synucleinopathies by a targeted and multiplex liquid chromatography coupled to mass spectrometry method.

We established a combination and ratio of alpha synuclein peptides, that distinguishing MSA from PD patients with good sensitivity and specificity (more than 80% for each). The AUC or sensitivity and specificity obtained for the ratio and combination were satisfying and similar to the clinical performance obtained for Aβ40/42 ratio that is use in AD clinical routine diagnostic. We can also distinguish PD patients from control and LBD pathology which is a strong finding and might revolutionize the synucleinopathies domain as the CSF biomarkers did for AD several years ago. The results reported here support the fact that this method will be used in clinical diagnosis but they may also be important for treatments targeting abnormal conformations of alpha synuclein.
Synuclein quantitation in plasma using LC-MRM

References


Synuclein quantitation in plasma using LC-MRM


## Synuclein quantitation in plasma using LC-MRM

### Table 1: Demographic and clinical characteristics of the plasma cohort. (UPDRS - Unified Parkinson’s Disease Rating Scale)

<table>
<thead>
<tr>
<th>Disease group</th>
<th>PD</th>
<th>LBD</th>
<th>MSA</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of plasma samples</td>
<td>82</td>
<td>32</td>
<td>8</td>
<td>21</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>72.1</td>
<td>70.3</td>
<td>69.6</td>
<td>68.9</td>
</tr>
<tr>
<td>Sex (%M)</td>
<td>61.3</td>
<td>84.4</td>
<td>40</td>
<td>66.7</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8.44</td>
<td>5.48</td>
<td>3.73</td>
<td>2.57</td>
</tr>
<tr>
<td>Cognitive score (MMSE, MOC or MATIS) %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>30.5</td>
<td>50.0</td>
<td>9.4</td>
<td>9.5</td>
</tr>
<tr>
<td>Negative</td>
<td>17.1</td>
<td>37.5</td>
<td>87.5</td>
<td>52.4</td>
</tr>
<tr>
<td>N/A</td>
<td>52.4</td>
<td>12.5</td>
<td>3.1</td>
<td>38.1</td>
</tr>
<tr>
<td>Hoehn and Yahr stage (UPDRS V) %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4.9</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>1.5</td>
<td>6.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>45.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>3.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>32.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>2.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Quantitation in plasma using LC-MRM

A summary of the clinical performance for each peptide, ratio and combination from α-syn and α/β-syn peptides. NA means non-assigned. AUC means area under the ROC curve.

<table>
<thead>
<tr>
<th>Peptide sequence</th>
<th>Position on α-syn</th>
<th>Clinical performance in order: p value / sensibility / specificity / AUC (area under the ROC curve)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PD vs LBD / PD vs MSA / PD vs control</td>
</tr>
<tr>
<td>α-syn EGVVAAAEK</td>
<td>13-21</td>
<td>0.344 / NA / NA / NA 0.989 / NA / NA / NA 0.028 / 0.830 / 0.670 0.656</td>
</tr>
<tr>
<td>α-syn QGVAEAAGK</td>
<td>34-32</td>
<td>0.033 / 0.490 / 0.780 / 0.629 0.989 / NA / NA 0.001 / 0.830 / 0.760 0.726</td>
</tr>
<tr>
<td>α-syn EGVLYVGSK</td>
<td>35-43</td>
<td>0.001 / 0.700 / 0.690 / 0.694 0.571 / NA / NA / NA 0.0001 / 0.840 / 0.760 0.787</td>
</tr>
<tr>
<td>α-syn</td>
<td>61-80</td>
<td>0.710 / NA / NA / NA 0.372 / NA / NA / NA 0.021 / 0.870 / 0.670 0.664</td>
</tr>
<tr>
<td>GAVVTGVTAQVK</td>
<td>81-96</td>
<td>0.341 / NA / NA / NA 0.436 / NA / NA / NA 0.213 / NA / NA / NA</td>
</tr>
<tr>
<td>EGVLYVGSK / α-syn</td>
<td>Peptide Ratio</td>
<td>0.0003 / 0.7 / 0.7 / 0.719 0.0084 / 0.80 / 0.85 / 0.784 &gt;0.05 / NA / NA / NA</td>
</tr>
</tbody>
</table>
Quantitation in plasma using LC-MRM

| (α-syn 3GAVVTGVTAVAQK)*1268) + (α/β-syn VGSK] * 0.0096545 | Peptide combination | 0.0001 / 0.7 / 0.68 / 0.743 | 0.0021 / 0.84 / 0.85 / 0.831 | 0.0003 / 0.83 / 0.58 / 0.757 |
Synuclein quantitation in plasma using LC-MRM

Figure list

Figure 1: Workflow of the analysis of the synucleins peptides in plasma by liquid chromatography-mass spectrometry with multiple reaction monitoring mode

Figure 2: Comparison of the PD group with the other synucleinpathies (MSA and LBD) and the control group with the model (α-syn [EQVTNVGAVVTGVTAQA]K* - 0.011268 + α/β-syn [EGVLYVGS]K * 0.0096545).

Figure 3A: ROC curve monitoring the clinical performance (sensitivity and specificity) for the peptide combination when PD is compared to LBD patients.

Figure 3B: ROC curve monitoring the clinical performance (sensitivity and specificity) for the peptide combination when PD is compared to MSA.

Conflict of Interest

The authors have no conflict of interest to report. Mass spectrometry experiments were carried out using the facilities of the Montpellier Proteomics Platform (PPM-PPC, BioCampus Montpellier). This article has been written in the context of the “innovation center” of Shimadzu Europa GmbH. All figures were created with the Biorender.com website.
Recombinant and fetal calf serum standards of synucleins in plasma

Acidic protein precipitation

Dessalting with RP-W tips

AssayMap Bravo

Agilent technologies.

Enzymatic digestion with trypsin/LysC

LC-SRM analysis

Shimadzu TQ8060.